Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 Meeting

May 17, 2017
by Alejandra Spangler

On Sunday, May 14th, at the American Urological Association (AUA) 2017 Meeting in Boston, MA, Photocure ASA announced the latest data from their Phase 3 study with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview®. This study showed that in 21.5% of the patients undergoing surveillance cystoscopy, a bladder cancer recurrence would have been missed using only white light as opposed to BLFC with Cysview. This is truly an important development in being able to detect a cancer with a 50-80% recurrence rate.

“This study shows that BLFC can provide a significant advantage for patients in terms of early detection of tumor recurrence which may improve treatment and therefore lead to better outcomes. 92.7% of the patients said it was worthwhile to undergo BLFC and 93.8% said that they would do it again. The results of the study show that BLFC will play a significant role in outpatient management of bladder cancer.” 

– J. Stephen Jones, MD, president of Cleveland Clinic Regional Hospitals and Family Health Centers

Click below to read the press release:

Photocure Press Release

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone